Page last updated: 2024-10-31

mitoxantrone and Peritoneal Carcinomatosis

mitoxantrone has been researched along with Peritoneal Carcinomatosis in 20 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Research Excerpts

ExcerptRelevanceReference
"The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part)."9.15A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011)
"A retrospective analysis of intraperitoneal mitoxantrone instillation therapy for malignant ascites in advanced breast and gynecologic pelvic cancers was performed to confirm the efficacy and safety of this therapy."8.82Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. ( Holtappels, M; Leder, G; Link, KH; Roitman, M; Runnebaum, I; Staib, L; Urbanzyk, H, 2003)
"We investigated the therapeutic efficiency of sulfonate-modified polyvinyl alcohol beads loaded with doxorubicin, irinotecan or mitoxantrone in vitro and in vivo in a model of experimental peritoneal carcinomatosis (PC)."7.75Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer. ( Faissner, R; Gasimova, L; Keese, M; Lewis, A; Löhr, M; Samel, S; Schwenke, K; Shang, E; Yagublu, V, 2009)
"A 44-year-old man who had achieved a complete remission of malignant peritoneal mesothelioma after the intraperitoneal administration of 25 mg/m2 mitoxantrone presented with clinical and radiological signs of intestinal obstruction suggestive of recurrent disease at about 2 years following the initial treatment."7.68Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. ( Gallee, MP; Kroon, BB; Rodenhuis, S; Taal, BG; Vlasveld, LT, 1992)
"The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part)."5.15A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011)
"A retrospective analysis of intraperitoneal mitoxantrone instillation therapy for malignant ascites in advanced breast and gynecologic pelvic cancers was performed to confirm the efficacy and safety of this therapy."4.82Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. ( Holtappels, M; Leder, G; Link, KH; Roitman, M; Runnebaum, I; Staib, L; Urbanzyk, H, 2003)
"We investigated the therapeutic efficiency of sulfonate-modified polyvinyl alcohol beads loaded with doxorubicin, irinotecan or mitoxantrone in vitro and in vivo in a model of experimental peritoneal carcinomatosis (PC)."3.75Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer. ( Faissner, R; Gasimova, L; Keese, M; Lewis, A; Löhr, M; Samel, S; Schwenke, K; Shang, E; Yagublu, V, 2009)
"A 44-year-old man who had achieved a complete remission of malignant peritoneal mesothelioma after the intraperitoneal administration of 25 mg/m2 mitoxantrone presented with clinical and radiological signs of intestinal obstruction suggestive of recurrent disease at about 2 years following the initial treatment."3.68Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. ( Gallee, MP; Kroon, BB; Rodenhuis, S; Taal, BG; Vlasveld, LT, 1992)
"35 ovarian cancer patients with ascites have been treated intraperitoneally with mitomycin C or mitoxantrone or interferon beta or tumor necrosis factor (TNF)."3.68[Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms]. ( Chronides, A; Diedrich, K; Krebs, D; Mallmann, P; Wagner, U; Werner, A, 1991)
" In the first trial, CDDP dosing was established as 90 mg/m2 with a perfusate time of 90 minutes and temperature of 41 degrees C."1.34Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. ( Benjamin, RS; Chase, JL; Cormier, JN; Feig, BW; Griffin, JR; Hunt, KK; Lim, SJ; Mansfield, PF; Pisters, PW; Pollock, RE, 2007)
"Patients with peritoneal carcinomatosis of various origin underwent surgery, including intestinal resections, with minimal residual disease."1.31Intraperitoneal mitoxantrone: a feasibility and pharmacokinetic study. ( Civalleri, D; De Cian, F; DeCian, F; Esposito, M; Lunardi, G; Pastrone, I; Steinweg, M; Vannozzi, MO; Viale, M, 2002)
"treatment with mitoxantrone."1.28Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ( Dubbelman, R; McVie, JG; Nagel, JD; ten Bokkel Huinink, WW; Varossieau, FJ, 1992)
" We have carried out studies to establish maximum tolerated doses as well as pharmacokinetic studies with i."1.27Phase-I study of intraperitoneal mitoxantrone--clinical and pharmacokinetic evaluation. ( Blöchl-Daum, B; Ehninger, G; Eichler, HG; Günther, E; Jakesz, R; Proksch, P; Rainer, H; Salzer, H; Schüller, J; Steger, G, 1987)
" We have carried out studies to establish maximum tolerated doses as well as pharmacokinetic studies with i."1.27Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluation. ( Blöchl-Daum, B; Ehninger, G; Eichler, HG; Günther, E; Jakesz, R; Proksch, B; Rainer, H; Salzer, H; Schüller, J; Steger, G, 1988)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19905 (25.00)18.7374
1990's6 (30.00)18.2507
2000's8 (40.00)29.6817
2010's1 (5.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Keese, M1
Gasimova, L1
Schwenke, K1
Yagublu, V1
Shang, E1
Faissner, R1
Lewis, A1
Samel, S1
Löhr, M1
Kehoe, SM1
Williams, NL1
Yakubu, R1
Levine, DA1
Chi, DS1
Sabbatini, PJ1
Aghajanian, CA1
Barakat, RR1
Abu-Rustum, NR1
Suzuki, E1
Furuse, J1
Ikeda, M1
Ishii, H1
Okusaka, T1
Nakachi, K1
Mitsunaga, S1
Ueno, H1
Morizane, C1
Link, KH2
Roitman, M1
Holtappels, M1
Runnebaum, I1
Urbanzyk, H1
Leder, G1
Staib, L2
Schmidt, U1
Dahlke, MH1
Klempnauer, J1
Schlitt, HJ1
Piso, P1
Lim, SJ1
Cormier, JN1
Feig, BW1
Mansfield, PF1
Benjamin, RS1
Griffin, JR1
Chase, JL1
Pisters, PW1
Pollock, RE1
Hunt, KK1
Genne, P1
Olsson, NO1
Gutierrez, G1
Duchamp, O1
Chauffert, B1
Hepp, G1
Butzer, U1
Böhm, W1
Beger, HG1
Volz, J1
Volz-Köster, S1
Kanis, S1
Klee, D1
Ahlert, C1
Melchert, F1
Civalleri, D1
Vannozzi, MO1
De Cian, F1
DeCian, F1
Lunardi, G1
Steinweg, M1
Pastrone, I1
Viale, M1
Esposito, M1
Verschraegen, CF1
Vlasveld, LT1
Taal, BG1
Kroon, BB1
Gallee, MP1
Rodenhuis, S1
Nagel, JD2
Varossieau, FJ1
Dubbelman, R1
ten Bokkel Huinink, WW1
McVie, JG2
Werner, A1
Mallmann, P1
Chronides, A1
Diedrich, K1
Wagner, U1
Krebs, D1
Los, G1
Markman, M1
Reichman, B1
Hakes, T1
Hoskins, W1
Rubin, S1
Jones, W1
Lewis, JL1
Kuhn, K1
Purea, H1
Selbach, J1
Westerhausen, M1
Blöchl-Daum, B3
Eichler, HG3
Rainer, H3
Jakesz, R2
Salzer, H2
Steger, G3
Schüller, J2
Günther, E2
Proksch, P1
Ehninger, G3
Proksch, B1
Mader, R1
Dittrich, C1
Moser, K1

Reviews

2 reviews available for mitoxantrone and Peritoneal Carcinomatosis

ArticleYear
Intraperitoneal chemotherapy with mitoxantrone in malignant ascites.
    Surgical oncology clinics of North America, 2003, Volume: 12, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Ascites; Carcinoma; Chemotherapy, Adjuvant; Dose-Response Relationsh

2003
Intracavitary therapies for mesothelioma.
    Current treatment options in oncology, 2001, Volume: 2, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj

2001

Trials

2 trials available for mitoxantrone and Peritoneal Carcinomatosis

ArticleYear
A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:3

    Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carci

2011
Coupling of mitoxantrone to poly(I).poly(C) reduces absorption after intraperitoneal administration.
    Chemotherapy, 1987, Volume: 33, Issue:3

    Topics: Absorption; Double-Blind Method; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Mitoxantr

1987

Other Studies

16 other studies available for mitoxantrone and Peritoneal Carcinomatosis

ArticleYear
Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer.
    International journal of cancer, 2009, Jun-01, Volume: 124, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Chemoembolization, Therap

2009
Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies.
    Gynecologic oncology, 2009, Volume: 113, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Cisplatin; Fallo

2009
Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2005, Volume: 31, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Female; Health Status; Hum

2005
Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.
    Annals of surgical oncology, 2007, Volume: 14, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Clinical Tr

2007
Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mice.
    Anti-cancer drug design, 1994, Volume: 9, Issue:2

    Topics: Animals; Carcinoma; Colonic Neoplasms; Drug Carriers; Electrochemistry; Female; Liposomes; Male; Mic

1994
Intraperitoneal regional chemotherapy with mitroxantrone.
    Cancer treatment and research, 1996, Volume: 81

    Topics: Antineoplastic Agents; Ascites; Humans; Mitoxantrone; Peritoneal Neoplasms

1996
Modulation of tumor-induced lethality after pneumoperitoneum in a mouse model.
    Cancer, 2000, Jul-15, Volume: 89, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Disease Models, Animal; Fema

2000
Intraperitoneal mitoxantrone: a feasibility and pharmacokinetic study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2002, Volume: 28, Issue:2

    Topics: Adult; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Sched

2002
Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone.
    Cancer chemotherapy and pharmacology, 1992, Volume: 29, Issue:5

    Topics: Adult; Biopsy; Fibrosis; Humans; Injections, Intraperitoneal; Intestinal Obstruction; Jejunal Diseas

1992
Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration.
    Cancer chemotherapy and pharmacology, 1992, Volume: 29, Issue:6

    Topics: Abdominal Neoplasms; Adult; Breast Neoplasms; Female; Humans; Injections, Intraperitoneal; Male; Mes

1992
[Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms].
    Zentralblatt fur Gynakologie, 1991, Volume: 113, Issue:23

    Topics: Ascites; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Interferon-

1991
Anti-tumor effect of cisplatin, carboplatin, mitoxantrone, and doxorubicin on peritoneal tumor growth after intraperitoneal and intravenous chemotherapy: a comparative study.
    Selective cancer therapeutics, 1990,Summer, Volume: 6, Issue:2

    Topics: Animals; Antineoplastic Agents; Body Weight; Carboplatin; Cisplatin; Doxorubicin; Injections, Intrap

1990
Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
    Acta medica Austriaca, 1989, Volume: 16, Issue:3-4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Fluor

1989
Treatment with locally applied mitoxantrone.
    Acta medica Austriaca, 1989, Volume: 16, Issue:3-4

    Topics: Catheters, Indwelling; Female; Humans; Infusions, Parenteral; Male; Mediastinal Neoplasms; Mitoxantr

1989
Phase-I study of intraperitoneal mitoxantrone--clinical and pharmacokinetic evaluation.
    Onkologie, 1987, Volume: 10, Issue:1

    Topics: Drug Evaluation; Female; Gastrointestinal Neoplasms; Humans; Infusions, Parenteral; Male; Mitoxantro

1987
Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluation.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:7

    Topics: Adult; Aged; Drug Evaluation; Female; Gastrointestinal Neoplasms; Humans; Infusions, Parenteral; Mal

1988